Biotech Investors & VC Firms in Shenzhen
13 firms in this list, with a median first check of $912.5K. 2 of them lead rounds. Generated from verified public data and updated continuously.
Fortune Venture Capital
ShenzhenSeed–Late Stage$425K – $73M
11 people
Green Pine Capital Partners
ShenzhenPre-Seed–Late Stage$425K – $150M
2 people
Blue Ocean Capital Group
ShenzhenLate Stage
21 people
Cowin Capital Group
ShenzhenSeed–Late Stage$1.4M – $50M
11 people
Shenzhen Capital Group
ShenzhenSeed–Growth$1.5M – $156M
3 people
Ming capital
ShenzhenSeed–Late Stage
6 people
EFung Capital
ShenzhenSeed–Growth
South China Venture Capital
ShenzhenSeed–Late Stage
4 people
Sangel Capital
ShenzhenSeed–Late Stage
Danen Capital
ShenzhenSeed–Growth
2 people
TriWise Capital
ShenzhenPre-Seed–Late Stage
1 person
CDF-Capital
ShenzhenSeed–Late Stage
Shenzhen Leaguer Tsing-Yuan Venture Capital Management Co., Ltd.
ShenzhenSeed–Series B
2 people
Frequently asked questions
- Who are the top biotech investors & vc firms in shenzhen?
- Top biotech investors & vc firms in shenzhen include Fortune Venture Capital, Green Pine Capital Partners, Blue Ocean Capital Group, Cowin Capital Group, Shenzhen Capital Group, Ming capital, EFung Capital, South China Venture Capital — 13 firms in total meet the criteria.
- What is the typical first check among biotech investors & vc firms in shenzhen?
- The median first check among the 13 biotech investors & vc firms in shenzhen tracked here is $912.5K.
- How many biotech investors & vc firms in shenzhen lead rounds?
- 2 of the 13 biotech investors & vc firms in shenzhen tracked here lead investment rounds.
Related lists
Investors & VC Firms in North America (14074)Investors & VC Firms in United States (13215)Investors & VC Firms in Europe (5565)Crypto & Web3 Investors & VC Firms (4819)Investors & VC Firms in Global (4147)SaaS Investors & VC Firms (3842)AI & Machine Learning Investors & VC Firms (3754)Fintech Investors & VC Firms (3710)Investors & VC Firms in Asia-Pacific (3567)Healthtech Investors & VC Firms (3393)
Data sourced from public filings and firms' own websites — see our methodology.





